| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 70.5% | Piper Sandler | → $20 | Initiates Coverage On | → Overweight |
What is the target price for Turnstone Biologics (TSBX)?
The latest price target for Turnstone Biologics (NASDAQ: TSBX) was reported by Piper Sandler on August 15, 2023. The analyst firm set a price target for $20.00 expecting TSBX to rise to within 12 months (a possible 70.50% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Turnstone Biologics (TSBX)?
The latest analyst rating for Turnstone Biologics (NASDAQ: TSBX) was provided by Piper Sandler, and Turnstone Biologics initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Turnstone Biologics (TSBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Turnstone Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Turnstone Biologics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Turnstone Biologics (TSBX) correct?
While ratings are subjective and will change, the latest Turnstone Biologics (TSBX) rating was a initiated with a price target of $0.00 to $20.00. The current price Turnstone Biologics (TSBX) is trading at is $11.73, which is within the analyst's predicted range.
